Skip to site menu Skip to page content
Logo Image
In Brief
Spotlight

Beyond the GLP-1RA weight loss ceiling

Eli Lilly’s retatrutide has crossed the 30% weight loss benchmark in some patients. Where do GLP-1RAs go from here?

Latest news

Lilly and Regeneron amongst first incumbents to FDA’s fast-track facility scheme 

Seven pharma companies have been selected for the FDA PreCheck pilot – a framework intended to bolster the US drug supply chain.

Anthropic debuts AI-driven pharma R&D tool, Claude Science

Claude Science launches as big tech companies increasingly eye expansion in the wider healthcare space.

Medical journal retracts Tavneos pivotal paper amid wider regulatory clampdown

This further weakens Amgen’s case for Tavneos’ continued use on the market as the drug comes under intense regulatory scrutiny.

US FDA rejects approval of Unicycive’s kidney disease therapy

The FDA did not raise concerns related to the clinical efficacy or safety data provided for OLC.

Eli Lilly and Innovent agree Verzenios commercialisation deal in China

Verzenios is a CDK4 and 6 inhibitor that has received approval in China for several indications related to breast cancer.

EAN 2026: following EU approval, AbbVie highlights Aquipta efficacy for acute migraine

AbbVie presented new results from the Phase III ECLIPSE trial (NCT06241313) at this year's Congress of the European Academy of Neurology (EAN).